Hepatocellular Carcinoma Enhancement on Contrast-enhanced CT and MR Imaging: Response Assessment After Treatment with Sorafenib: Preliminary Results

Overview

Journal Radiol Med

Specialty Radiology

Date 2013 Dec 4

PMID 24297581

Citations 15

Authors

Giuseppe Salvaggio

Alessandro Furlan

Francesco Agnello

Giuseppe Cabibbo

Daniele Marin

Lydia Giannitrapani

Chiara Genco

Massimo Midiri

Roberto Lagalla

Giuseppe Brancatelli

Affiliations

Soon will be listed here.

Abstract

Purpose: This study was undertaken to compare response evaluation criteria in solid tumours (RECIST) 1.1 and modified RECIST (mRECIST) in patients with unresectable hepatocellular carcinoma (HCC) on sorafenib, and to describe HCC enhancement changes before and after sorafenib treatment.

Methods And Materials: Seventeen patients (12 men, 5 women; mean age 69 years; age range 58-79 years) were included. Tumour response was assessed according to RECIST and mRECIST. Two readers placed a region of interest (ROI) within each target lesion, on the portion showing enhancement during the arterial phase. The lesion attenuation values measured within the ROIs on computed tomography or the signal intensity measured on magnetic resonance imaging, during the unenhanced phase, hepatic arterial phase and venous phase were recorded. Changes in arterial and venous contrast enhancement before and after treatment were compared among the mRECIST groups using Mann-Whitney U test.

Results: Agreement between mRECIST and RECIST was good (Cohen's k coefficient, 0.791). Patients with partial response had a greater decrease in arterial enhancement (-79.8%) than did patients with stable disease (SD) (-24.8%; p = 0.011) or progressive disease (PD) (-32.9%; p = 0.034). No statistically significant difference in arterial enhancement variation was found among patients with SD and PD. No statistically significant difference in venous enhancement was found among the mRECIST groups.

Conclusions: mRECIST showed a more favourable response compared to RECIST 1.1 in patients with unresectable HCC receiving sorafenib.

Citing Articles

Review of the Application of Dual Drug Delivery Nanotheranostic Agents in the Diagnosis and Treatment of Liver Cancer.

Han Q, Du L, Zhu L, Yu D Molecules. 2023; 28(20).

PMID: 37894483 PMC: 10608862. DOI: 10.3390/molecules28207004.

Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy.

Ippolito D, Maino C, Gatti M, Marra P, Faletti R, Cortese F World J Gastroenterol. 2023; 29(11):1669-1684.

PMID: 37077517 PMC: 10107213. DOI: 10.3748/wjg.v29.i11.1669.

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q BMJ Open. 2022; 12(6):e052294.

PMID: 35649603 PMC: 9161105. DOI: 10.1136/bmjopen-2021-052294.

A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response.

Granata V, Fusco R, Salati S, Petrillo A, Di Bernardo E, Grassi R Int J Environ Res Public Health. 2021; 18(11).

PMID: 34073865 PMC: 8197272. DOI: 10.3390/ijerph18115592.

Abbreviated MRI Protocol for the Assessment of Ablated Area in HCC Patients.

Granata V, Grassi R, Fusco R, Setola S, Belli A, Piccirillo M Int J Environ Res Public Health. 2021; 18(7).

PMID: 33808466 PMC: 8037601. DOI: 10.3390/ijerph18073598.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

Sabir A, Schor-Bardach R, Wilcox C, Rahmanuddin S, Atkins M, Kruskal J . Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol. 2008; 191(1):133-9. DOI: 10.2214/AJR.07.2848. View

Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard J, Lim H . Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res. 2011; 17(13):4504-12. DOI: 10.1158/1078-0432.CCR-10-1708. View

Horger M, Lauer U, Schraml C, Berg C, Koppenhofer U, Claussen C . Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer. 2009; 9:208. PMC: 2714320. DOI: 10.1186/1471-2407-9-208. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Sullivan D, Gatsonis C . Response to treatment series: part 1 and introduction, measuring tumor response--challenges in the era of molecular medicine. AJR Am J Roentgenol. 2011; 197(1):15-7. DOI: 10.2214/AJR.11.7083. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Yaghmai V, Miller F, Rezai P, Benson 3rd A, Salem R . Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. AJR Am J Roentgenol. 2011; 197(1):18-27. DOI: 10.2214/AJR.11.6581. View

10.

Choi H, Charnsangavej C, de Castro Faria S, Tamm E, Benjamin R, Johnson M . CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004; 183(6):1619-28. DOI: 10.2214/ajr.183.6.01831619. View

11.

Kim K, Lee J, Choi B . Assessment of the treatment response of HCC. Abdom Imaging. 2011; 36(3):300-14. DOI: 10.1007/s00261-011-9683-3. View

12.

Jiang T, Kambadakone A, Kulkarni N, Zhu A, Sahani D . Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol. 2011; 47(1):11-7. DOI: 10.1097/RLI.0b013e3182199bb5. View

13.

Choi H, Charnsangavej C, Faria S, Macapinlac H, Burgess M, Patel S . Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25(13):1753-9. DOI: 10.1200/JCO.2006.07.3049. View

14.

Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C . Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2011; 118(1):147-56. DOI: 10.1002/cncr.26255. View

15.

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

16.

Spira D, Fenchel M, Lauer U, Claussen C, Gregor M, Bitzer M . Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol. 2010; 18(1):89-96. DOI: 10.1016/j.acra.2010.08.008. View

17.

Wang J, Chen L, Tsang Y, Liu T, Shih T . Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol. 2004; 183(3):713-9. DOI: 10.2214/ajr.183.3.1830713. View

18.

Roberts L . Sorafenib in liver cancer--just the beginning. N Engl J Med. 2008; 359(4):420-2. DOI: 10.1056/NEJMe0802241. View

19.

Maksimovic O, Schraml C, Hartmann J, Bitzer M, Claussen C, Pintoffl J . Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am J Roentgenol. 2009; 194(1):5-14. DOI: 10.2214/AJR.09.2744. View

20.

Smith A, Lieber M, Shah S . Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2009; 194(1):157-65. DOI: 10.2214/AJR.09.2941. View